• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

神经元特异性烯醇化酶在晚期和转移性非神经内分泌非小细胞肺癌患者中的预后价值。

Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.

机构信息

Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China.

Graduate School, Shandong First Medical University and Academy of Medical Sciences, Jinan, P.R. China.

出版信息

Biosci Rep. 2021 Aug 27;41(8). doi: 10.1042/BSR20210866.

DOI:10.1042/BSR20210866
PMID:34286335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8329647/
Abstract

BACKGROUND

Increased serum neuron-specific enolase (NSE) level was found in a substantial proportion (30-69%) of patients with non-small-cell lung cancer (NSCLC), but little was known about the clinical properties of NSE in NSCLC.

OBJECTIVE

We aimed to assess the level of serum NSE to predict prognosis and treatment response in patients with advanced or metastatic non-neuroendocrine NSCLC.

METHODS

We retrospectively analyzed 363 patients with advanced and metastatic NSCLC between January 2011 and October 2016. The serum NSE level was measured before initiation of treatment.

RESULTS

Patients with high NSE level (≥26.1 ng/ml) showed significantly shorter progression-free survival (PFS) (5.69 vs 8.09 months; P=0.02) and significantly shorter overall survival (OS) than patients with low NSE level (11.41 vs 24.31 months; P=0.01). NSE level was an independent prognostic factor for short PFS (univariate analysis, hazard ratio [HR] = 2.40 (1.71-3.38), P<0.001; multivariate analysis, [HR] = 1.81 (1.28-2.56), P=0.001) and OS (univariate analysis, [HR] = 2.40 (1.71-3.37), P<0.001; multivariate analysis, [HR] = 1.76 (1.24-2.50), P=0.002).

CONCLUSION

The survival of NSCLC patients with high serum NSE level was shorter than that of NSCLC patients with low serum NSE levels. Serum NSE level was a predictor of treatment response and an independent prognostic factor.

摘要

背景

在相当一部分（30-69%）非小细胞肺癌（NSCLC）患者中发现血清神经元特异性烯醇化酶（NSE）水平升高，但对于 NSCLC 中 NSE 的临床特征知之甚少。

目的

我们旨在评估血清 NSE 水平，以预测晚期或转移性非神经内分泌 NSCLC 患者的预后和治疗反应。

方法

我们回顾性分析了 2011 年 1 月至 2016 年 10 月期间 363 例晚期和转移性 NSCLC 患者。在开始治疗前测量血清 NSE 水平。

结果

高 NSE 水平（≥26.1ng/ml）患者的无进展生存期（PFS）（5.69 个月比 8.09 个月；P=0.02）和总生存期（OS）（11.41 个月比 24.31 个月；P=0.01）明显短于低 NSE 水平患者。NSE 水平是 PFS （单因素分析，HR=2.40（1.71-3.38），P<0.001；多因素分析，HR=1.81（1.28-2.56），P=0.001）和 OS （单因素分析，HR=2.40（1.71-3.37），P<0.001；多因素分析，HR=1.76（1.24-2.50），P=0.002）的独立预后因素。

结论

高血清 NSE 水平的 NSCLC 患者的生存时间短于低血清 NSE 水平的 NSCLC 患者。血清 NSE 水平是治疗反应的预测指标，也是独立的预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/686741eb4a5b/bsr-41-bsr20210866-g8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/7df1b43d2fa5/bsr-41-bsr20210866-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/c324e4ba41d3/bsr-41-bsr20210866-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/d9e865cb3eca/bsr-41-bsr20210866-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/7f118d2edf64/bsr-41-bsr20210866-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/2c72e0f14d7a/bsr-41-bsr20210866-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/781e8201af41/bsr-41-bsr20210866-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/0d8fab69b6d2/bsr-41-bsr20210866-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/686741eb4a5b/bsr-41-bsr20210866-g8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/7df1b43d2fa5/bsr-41-bsr20210866-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/c324e4ba41d3/bsr-41-bsr20210866-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/d9e865cb3eca/bsr-41-bsr20210866-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/7f118d2edf64/bsr-41-bsr20210866-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/2c72e0f14d7a/bsr-41-bsr20210866-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/781e8201af41/bsr-41-bsr20210866-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/0d8fab69b6d2/bsr-41-bsr20210866-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa4e/8329647/686741eb4a5b/bsr-41-bsr20210866-g8.jpg

相似文献

1
Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.神经元特异性烯醇化酶在晚期和转移性非神经内分泌非小细胞肺癌患者中的预后价值。
Biosci Rep. 2021 Aug 27;41(8). doi: 10.1042/BSR20210866.
2
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.血清神经元特异性烯醇化酶水平可预测携带表皮生长因子受体（EGFR）突变的非小细胞肺癌患者一线表皮生长因子受体酪氨酸激酶抑制剂的疗效。
Clin Lung Cancer. 2016 Jul;17(4):245-252.e1. doi: 10.1016/j.cllc.2015.11.012. Epub 2015 Nov 30.
3
[Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].[治疗前血清神经元特异性烯醇化酶在预测晚期非小细胞肺癌脑转移及预后中的意义]
Zhonghua Zhong Liu Za Zhi. 2015 Jul;37(7):508-11.
4
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.细胞角蛋白19片段、神经元特异性烯醇化酶与非小细胞肺癌的预后：621例患者的前瞻性研究
Lung Cancer. 2001 Feb-Mar;31(2-3):221-31. doi: 10.1016/s0169-5002(00)00186-0.
5
Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.血清人附睾分泌蛋白4（HE4）是非小细胞肺癌潜在的预后生物标志物。
Clin Lab. 2018 Sep 1;64(9):1421-1428. doi: 10.7754/Clin.Lab.2018.180222.
6
Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.神经元特异性烯醇化酶预测一线 PD-1/PD-L1 抑制剂治疗的晚期小细胞肺癌患者的预后。
Medicine (Baltimore). 2021 Sep 10;100(36):e27029. doi: 10.1097/MD.0000000000027029.
7
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.血液血清淀粉样蛋白 A 作为 PD-L1 过表达晚期非小细胞肺癌患者接受 pembrolizumab 疗效的潜在生物标志物：探索性“FoRECATT”研究的结果。
Cancer Immunol Immunother. 2021 Jun;70(6):1583-1592. doi: 10.1007/s00262-020-02788-1. Epub 2020 Nov 24.
8
The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.循环神经内分泌标志物嗜铬粒蛋白A、胃泌素释放肽前体和神经元特异性烯醇化酶在晚期非小细胞肺癌患者中的预后意义。
Tumour Biol. 2006;27(1):8-16. doi: 10.1159/000090151. Epub 2005 Dec 8.
9
Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.化疗第一周期后正常血清神经元特异性烯醇化酶（NSE）值：小细胞肺癌患者完全缓解和生存的早期预测指标。
Cancer. 1998 Mar 15;82(6):1049-55. doi: 10.1002/(sici)1097-0142(19980315)82:6<1049::aid-cncr6>3.0.co;2-9.
10
The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.Delta-like3 和血清 NSE 对评估晚期小细胞肺癌患者化疗反应和预后的预测价值：一项观察性研究。
Medicine (Baltimore). 2024 Jun 7;103(23):e38487. doi: 10.1097/MD.0000000000038487.

引用本文的文献

1
Clinical value of ENO2 in serum extracellular vesicles for the diagnosis and prognosis of diffuse large B-cell lymphoma patients.血清细胞外囊泡中ENO2对弥漫性大B细胞淋巴瘤患者诊断和预后的临床价值
Clin Transl Oncol. 2025 Aug 22. doi: 10.1007/s12094-025-04030-9.
2
The Prognostic Value of Nutritional and Immune Indices for Stage IB Non-Small Cell Lung Cancer Patients: Insights From a Retrospective Cohort Study.营养和免疫指标对ⅠB期非小细胞肺癌患者的预后价值：一项回顾性队列研究的见解
Cancer Med. 2025 Aug;14(15):e71089. doi: 10.1002/cam4.71089.
3
The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets.
黏蛋白家族在肺癌中的多方面作用：从预后生物标志物到有前景的靶点。
Front Immunol. 2025 Jun 27;16:1608140. doi: 10.3389/fimmu.2025.1608140. eCollection 2025.
4
Impedimetric Biosensors for the Quantification of Serum Biomarkers for Early Detection of Lung Cancer.用于定量检测血清生物标志物以早期诊断肺癌的阻抗式生物传感器。
Biosensors (Basel). 2024 Dec 18;14(12):624. doi: 10.3390/bios14120624.
5
Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression.基于 LASSO 回归的晚期非小细胞肺癌患者生存预测模型的建立与验证。
Front Immunol. 2024 Aug 2;15:1431150. doi: 10.3389/fimmu.2024.1431150. eCollection 2024.
6
Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model.肺腺癌的综合蛋白质组学分析：一种创新预后模型的建立与验证
Transl Cancer Res. 2024 May 31;13(5):2187-2207. doi: 10.21037/tcr-23-1940. Epub 2024 May 29.
7
Tumor biomarkers for diagnosis, prognosis and targeted therapy.肿瘤标志物用于诊断、预后和靶向治疗。
Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2.
8
Beyond , emerging roles and targeting strategies of other enolases in cancers.此外，其他烯醇化酶在癌症中的新作用和靶向策略。
Mol Ther Oncolytics. 2023 Nov 10;31:100750. doi: 10.1016/j.omto.2023.100750. eCollection 2023 Dec 19.
9
Assessment of Specific Tumoral Markers, Inflammatory Status, and Vitamin D Metabolism before and after the First Chemotherapy Cycle in Patients with Lung Cancer.肺癌患者首个化疗周期前后特定肿瘤标志物、炎症状态及维生素D代谢的评估
Biology (Basel). 2022 Jul 8;11(7):1033. doi: 10.3390/biology11071033.
10
Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.IA期非小细胞肺癌术后的术后静脉血栓栓塞：一项单中心前瞻性队列研究。
Thorac Cancer. 2022 May;13(9):1258-1266. doi: 10.1111/1759-7714.14373. Epub 2022 Mar 22.